Melanoma is a tumour arising from melanocytes of the basal layer of the epidermis. The major cause is considered overexposure to sunlight. Global incidence rates of melanoma are rising particularly in persons >65 yrs
although the disease is not uncommon in younger persons. Early stage melanomas (Stage I and some Stage II) can be treated with surgery.
However, for later stages (Stage III and Stage IV) most patients will not be cured with 5 year survival rates ranging from 50-70%.
Newly approved treatments such as Bristol Myers Squibb’s ipilimumab (Yervoy), a CTLA-4 monoclonal antibody improve overall survival in melanoma patients,
although treatment is associated with a substantial risk of immune related reactions. Other advances include the BRAF kinase inhibitor vemurafenib.
This MarketVIEW analysis investigates the proposition of new therapeutic vaccines being used in the adjunctive treatment of melanoma.
Potential indications, patient segmentation and vaccine target product profiles are discussed with a particular emphasis on GSK’s GSK2132231A.
The commercial potential of putative melanoma vaccine(s) is estimated with HI and LO scenarios postulated for the major Western markets to 2030.
The product is comprised of a comprehensive value/volume MS Excel-based model + Summary executive presentation and is designed to aid early stage commercial
decision making in the field of oncology therapeutic vaccines.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL